BURLINGTON, Mass., Feb. 9 /PRNewswire/ -- LeMaitre Vascular today acquired Endomed, Inc., a maker of endovascular stent grafts for the minimally invasive treatment of thoracic and abdominal aortic aneurysms. Endomed's products are CE marked and have been sold in Europe and other international markets since 2002.
Endomed's products allow surgeons to treat aortic aneurysms through a small incision in the leg rather than through invasive open surgery of the thorax or abdomen. Endomed is one of only a limited number of companies in the world with a CE-marked stent graft for the treatment of disease in the thoracic aorta. Endomed's aorto-uni-iliac stent graft is in a Phase I clinical trial in the United States. Endomed's products are protected by a comprehensive portfolio of U.S. and foreign patents.
'Vascular medicine is moving toward minimally invasive repair at a rapid pace,' said George W. LeMaitre, Chairman, President, & CEO. 'We are pleased to be part of the endovascular revolution. When cutting edge technology improves patient care, everyone benefits.'
Endomed was founded and majority owned by Edward Diethrich, M.D., founder of the Arizona Heart Institute and Chief of Cardiovascular Surgery at the Arizona Heart Hospital.
Financial terms of the acquisition were undisclosed. The acquisition was funded by debt provided by Brown Brothers Harriman.
Founded in 1983, LeMaitre is a privately held vascular device company headquartered in Burlington, Massachusetts. LeMaitre designs, manufactures and markets vascular surgery devices. LeMaitre has manufacturing facilities in Burlington (MA), St. Petersburg (FL) & Brymbo (UK) and international headquarters in Frankfurt (Germany).
Contact: Sandra Millar LeMaitre Vascular, Inc. 781-608-3737 781-221-2223 smillar@lemaitre.comhttp://www.lemaitre.com/
LeMaitre VascularCONTACT: Sandra Millar of LeMaitre Vascular, Inc., +1-781-608-3737,+1-781-221-2223, smillar@lemaitre.com
Web site: http://www.lemaitre.com/
